Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Hold” by Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received an average recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $76.50.

Several research analysts have recently commented on PBH shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Jefferies Financial Group decreased their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th.

Prestige Consumer Healthcare Trading Down 4.9%

Shares of PBH opened at $55.88 on Thursday. The company has a market capitalization of $2.64 billion, a P/E ratio of 14.78, a P/E/G ratio of 1.74 and a beta of 0.47. Prestige Consumer Healthcare has a one year low of $51.24 and a one year high of $89.37. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The stock has a 50-day moving average price of $61.36 and a 200 day moving average price of $62.10.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.54 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its position in shares of Prestige Consumer Healthcare by 4.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock worth $161,723,000 after purchasing an additional 119,459 shares during the period. State Street Corp raised its position in shares of Prestige Consumer Healthcare by 1.4% during the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after purchasing an additional 27,721 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Prestige Consumer Healthcare by 1.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after purchasing an additional 21,085 shares during the period. Morgan Stanley raised its position in shares of Prestige Consumer Healthcare by 6.3% during the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after purchasing an additional 71,078 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Prestige Consumer Healthcare by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock worth $45,568,000 after purchasing an additional 35,126 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).